Cardiac Biomarkers Market To Reach $51.19 Billion By 2030

May 2025 | Report Format: Electronic (PDF)

Cardiac Biomarkers Market Growth & Trends

The global cardiac biomarkers market is anticipated to reach USD 51.19 billion by 2030 and is anticipated to expand at a CAGR of 14.1% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.

According to the report by Cleveland Clinic, more than 18 million adults in the U.S. were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S., and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.

The rising adoption of biomarkers in risk stratification and diagnosis of acute coronary syndrome is increasing the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making the use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin.

key Request a free sample copy or view report summary: Cardiac Biomarkers Market Report

Cardiac Biomarkers Market Report Highlights

In terms of type, the troponin segment held the largest revenue share of over 35.5% in 2024 owing to its high usage in cardiovascular disease diagnosis
Based on application, the acute coronary syndrome segment is expected to grow at the fastest CAGR during 2025 – 2030
In terms of end use, laboratory testing segment dominated the market in 2024
North America dominated the global market in 2024 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
Key players operating in the cardiac biomarkers market include Abbott, Quidel Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Danaher, BIOMÉRIEUX, Bio-Rad Laboratories Inc, Randox Laboratories Ltd, Creative Diagnostics, Life Diagnostics
The rise in the availability of novel assays is one of the major drivers anticipated to boost market growth in the upcoming years. For instance, in October 2023, Mindray launched two highly sensitive cardiac biomarkers assays, hs-cTnI Assay, and NT-proBNP Assay, to diversify its portfolio in cardio biomarkers to provide enhanced cardiovascular disease care.